The addition of Research Across America's sites means that Synexus can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
Synexus has purchased Research Across America (RAA) for an undisclosed sum. RAA was founded in 1989 by Dr. Jeffrey Adelglass, and has grown from a single location to multiple dedicated research sites across the U.S. Its sites have conducted over 2,000 clinical trials.
Synexus already owns 25 research sites in 10 countries. The addition of RAA’s sites means that it can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
“Synexus already has a strong international footprint. This latest acquisition is an important one for Synexus as it marks our entry into the US market, giving us truly global capability,” noted CEO Christophe Berthoux. “We spent a great deal of time considering an appropriate partner and selected Research Across America as it has a number of synergies with the Synexus model. In addition, by adding these sites to our network we have also gained expertise in areas, such as dermatology and generics, enabling us to further support our client base.”
Read the full article.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.